Cargando…

GABAergic neuroactive steroids: a new frontier in bipolar disorders?

Neurosteroids are synthesized in the brain and modulate brain excitability. There is increasing evidence of their sedative, anesthetic and antiseizure properties, as well as their influence on mood. Currently neurosteroids are classified as pregnane neurosteroids (allopregnanolone and allotetrahydro...

Descripción completa

Detalles Bibliográficos
Autores principales: Carta, Mauro Giovanni, Bhat, Krishna M, Preti, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573983/
https://www.ncbi.nlm.nih.gov/pubmed/23253178
http://dx.doi.org/10.1186/1744-9081-8-61
_version_ 1782259540505395200
author Carta, Mauro Giovanni
Bhat, Krishna M
Preti, Antonio
author_facet Carta, Mauro Giovanni
Bhat, Krishna M
Preti, Antonio
author_sort Carta, Mauro Giovanni
collection PubMed
description Neurosteroids are synthesized in the brain and modulate brain excitability. There is increasing evidence of their sedative, anesthetic and antiseizure properties, as well as their influence on mood. Currently neurosteroids are classified as pregnane neurosteroids (allopregnanolone and allotetrahydrodeoxycorticosterone), androstane neurosteroids (androstanediol and etiocholanone) or sulfated neurosteroids (pregnenolone sulfate and dehydroepiandrosterone sulfate). Both preclinical and clinical findings indicate that progesterone derivative neurosteroids such as allopregnanolone and allotetrahydrodeoxycorticosterone play a role in mood disorders. Clozapine and olanzapine, which were shown to be effective in stabilizing bipolar disorder, elevate pregnenolone levels in rat hippocampus, cerebral cortex, and serum. In lithium-treated mice, the blood levels of allopregnanolone and pregnenolone were elevated compared to control levels. Women diagnosed with bipolar disorder typically show symptomatic exacerbation in relation to the menstrual cycle, and show vulnerability to the onset or recurrence of mood disorders immediately after giving birth, when the levels of neurosteroid derivatives of progesterone drop. Whereas in women who had recovered from bipolar disorder, the plasma concentration of allopregnanolone was elevated compared to either healthy controls or women with major depressive disorder during the premenstrual period. During depressive episodes, blood level of allopregnanolone is low. Treatment with fluoxetine tends to stabilize the levels of neurosteroids in depression. These findings converge to suggest that these steroids have significant mood-stabilizing effect. This hypothesis is consistent with the observation that a number of anticonvulsants are effective therapies for bipolar disorder, a finding also consistent with the antiseizure properties of neurosteroids. Further exploration of action of neuroactive steroids is likely to open new frontiers in the investigation of the etiology and treatment of mood disorders, particularly bipolar disorders.
format Online
Article
Text
id pubmed-3573983
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35739832013-02-16 GABAergic neuroactive steroids: a new frontier in bipolar disorders? Carta, Mauro Giovanni Bhat, Krishna M Preti, Antonio Behav Brain Funct Review Neurosteroids are synthesized in the brain and modulate brain excitability. There is increasing evidence of their sedative, anesthetic and antiseizure properties, as well as their influence on mood. Currently neurosteroids are classified as pregnane neurosteroids (allopregnanolone and allotetrahydrodeoxycorticosterone), androstane neurosteroids (androstanediol and etiocholanone) or sulfated neurosteroids (pregnenolone sulfate and dehydroepiandrosterone sulfate). Both preclinical and clinical findings indicate that progesterone derivative neurosteroids such as allopregnanolone and allotetrahydrodeoxycorticosterone play a role in mood disorders. Clozapine and olanzapine, which were shown to be effective in stabilizing bipolar disorder, elevate pregnenolone levels in rat hippocampus, cerebral cortex, and serum. In lithium-treated mice, the blood levels of allopregnanolone and pregnenolone were elevated compared to control levels. Women diagnosed with bipolar disorder typically show symptomatic exacerbation in relation to the menstrual cycle, and show vulnerability to the onset or recurrence of mood disorders immediately after giving birth, when the levels of neurosteroid derivatives of progesterone drop. Whereas in women who had recovered from bipolar disorder, the plasma concentration of allopregnanolone was elevated compared to either healthy controls or women with major depressive disorder during the premenstrual period. During depressive episodes, blood level of allopregnanolone is low. Treatment with fluoxetine tends to stabilize the levels of neurosteroids in depression. These findings converge to suggest that these steroids have significant mood-stabilizing effect. This hypothesis is consistent with the observation that a number of anticonvulsants are effective therapies for bipolar disorder, a finding also consistent with the antiseizure properties of neurosteroids. Further exploration of action of neuroactive steroids is likely to open new frontiers in the investigation of the etiology and treatment of mood disorders, particularly bipolar disorders. BioMed Central 2012-12-19 /pmc/articles/PMC3573983/ /pubmed/23253178 http://dx.doi.org/10.1186/1744-9081-8-61 Text en Copyright ©2012 Carta et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Carta, Mauro Giovanni
Bhat, Krishna M
Preti, Antonio
GABAergic neuroactive steroids: a new frontier in bipolar disorders?
title GABAergic neuroactive steroids: a new frontier in bipolar disorders?
title_full GABAergic neuroactive steroids: a new frontier in bipolar disorders?
title_fullStr GABAergic neuroactive steroids: a new frontier in bipolar disorders?
title_full_unstemmed GABAergic neuroactive steroids: a new frontier in bipolar disorders?
title_short GABAergic neuroactive steroids: a new frontier in bipolar disorders?
title_sort gabaergic neuroactive steroids: a new frontier in bipolar disorders?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573983/
https://www.ncbi.nlm.nih.gov/pubmed/23253178
http://dx.doi.org/10.1186/1744-9081-8-61
work_keys_str_mv AT cartamaurogiovanni gabaergicneuroactivesteroidsanewfrontierinbipolardisorders
AT bhatkrishnam gabaergicneuroactivesteroidsanewfrontierinbipolardisorders
AT pretiantonio gabaergicneuroactivesteroidsanewfrontierinbipolardisorders